We are live on
!
Find out more
SCM
Squadron Capital Management Portfolio holdings
AUM
$322M
This Fund
S&P 500
This Quarter
Est. Return
+39.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$36.9M
(+16%)
Cap. Flow
+$3.66M
Cap. Flow
% of AUM
1.34%
Top 10 Holdings %
Top 10 Hldgs %
67.07%
Holding
52
New
19
Increased
8
Reduced
8
Closed
15
Avg Time Held Equity + Options
0.5
quarters
Top 10 Avg Time Held Equity + Options
0.7
quarters
Top 20 Avg Time Held Equity + Options
0.5
quarters
Avg Time Held Equity only
0.6
quarters
Top 10 Avg Time Held Equity only
0.7
quarters
Top 20 Avg Time Held Equity only
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$9.38M |
| 2 |
ANL
Adlai Nortye Group ADS
ANL
|
+$8.46M |
| 3 |
Relmada Therapeutics
RLMD
|
+$8.4M |
| 4 |
Nektar Therapeutics
NKTR
|
+$7.12M |
| 5 |
Relay Therapeutics
RLAY
|
+$6.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MAZE
Maze Therapeutics
MAZE
|
+$10.3M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$7.68M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$6.55M |
| 4 |
UPB
Upstream Bio Inc
UPB
|
+$6.26M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$4.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.59% |
| 2 | Miscellaneous | 8.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Relmada Therapeutics
RLMD
$363M
| $59M | 21.61% |
8,474,571
+1,774,571
| +26% | +$8.4M |
2025 Q4
1 quarter
|
|
2
Cogent Biosciences
COGT
$5.34B
| $30.3M | 11.11% |
787,492
+7,492
| +1% | +$277K |
2025 Q4
1 quarter
|
|
|
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
| $19.8M | 7.27% |
985,100
+285,100
| +41% | +$4.6M |
2025 Q4
1 quarter
|
|
4
Kodiak Sciences
KOD
$6.25B
| $14.5M | 5.31% |
380,000
+88,290
| +30% | +$2.28M |
2025 Q4
1 quarter
|
|
|
ABVX
5
Abivax
ABVX
$7.68B
| $14.5M | 5.3% |
130,000
-15,000
| -10% | -$1.78M |
2025 Q4
1 quarter
|
|
6
Edgewise Therapeutics
EWTX
$4.26B
| $11M | 4.04% |
350,000
| – | – |
2025 Q4
1 quarter
|
|
|
7
Nektar Therapeutics
NKTR
$1.41B
| $8.99M | 3.3% |
+125,000
| New | +$7.12M |
2026 Q1
0 quarters
|
|
|
ANL
8
Adlai Nortye Group ADS
ANL
$1.02B
| $8.76M | 3.21% |
+1,265,231
| New | +$8.46M |
2026 Q1
0 quarters
|
|
|
9
Zentalis Pharmaceuticals
ZNTL
$249M
| $8.5M | 3.11% |
+3,631,000
| New | +$9.38M |
2026 Q1
0 quarters
|
|
|
MAZE
10
Maze Therapeutics
MAZE
$1.51B
| $7.69M | 2.82% |
257,500
-232,500
| -47% | -$10.3M |
2025 Q4
1 quarter
|
|
11
SCYNEXIS
SCYX
$40.7M
| $6.98M | 2.56% |
+951,087
| New | +$5.88M |
2026 Q1
0 quarters
|
|
|
12
Relay Therapeutics
RLAY
$3.96B
| $6.69M | 2.45% |
+672,500
| New | +$6.02M |
2026 Q1
0 quarters
|
|
|
KALV
13
CALL
DELISTED
KalVista Pharmaceuticals
KALV
| $6.34M | 2.32% |
+315,000
| New | +$5.08M |
2026 Q1
0 quarters
|
|
14
C4 Therapeutics
CCCC
$388M
| $5.92M | 2.17% |
+2,250,000
| New | +$5.3M |
2026 Q1
0 quarters
|
|
15
Inhibikase Therapeutics
IKT
$272M
| $5.88M | 2.15% |
3,500,000
-725,000
| -17% | -$1.29M |
2025 Q4
1 quarter
|
|
16
Palisade Bio
PALI
$270M
| $5.25M | 1.92% |
3,000,000
-1,500,000
| -33% | -$2.73M |
2025 Q4
1 quarter
|
|
|
EPRX
17
Eupraxia Pharmaceuticals
EPRX
$494M
| $4.92M | 1.8% |
680,000
+180,000
| +36% | +$1.45M |
2025 Q4
1 quarter
|
|
18
GH Research
GHRS
$1.45B
| $4.57M | 1.67% |
325,000
+10,000
| +3% | +$153K |
2025 Q4
1 quarter
|
|
19
PUT
Karyopharm Therapeutics
KPTI
$14.1M
| $4.18M | 1.53% |
+750,000
| New | +$5.72M |
2026 Q1
0 quarters
|
|
20
ProMIS Neurosciences
PMN
$86.2M
| $4.13M | 1.51% |
+324,977
| New | +$4.85M |
2026 Q1
0 quarters
|
|
21
PUT
IDEAYA Biosciences
IDYA
$3.48B
| $4M | 1.47% |
+120,000
| New | +$4.03M |
2026 Q1
0 quarters
|
|
22
Lipocine
LPCN
$14.3M
| $3.6M | 1.32% |
450,000
-80,000
| -15% | -$697K |
2025 Q4
1 quarter
|
|
|
23
CALL
IDEAYA Biosciences
IDYA
$3.48B
| $3.48M | 1.27% |
+104,300
| New | +$3.5M |
2026 Q1
0 quarters
|
|
|
IVA
24
Inventiva
IVA
$751M
| $2.97M | 1.09% |
535,000
+235,000
| +78% | +$1.43M |
2025 Q4
1 quarter
|
|
25
ALX Oncology
ALXO
$174M
| $2.93M | 1.07% |
+1,460,000
| New | +$2.78M |
2026 Q1
0 quarters
|
|
Similar funds
SST
CW
WW
NAG
JGIA
EI
KF
QFPS
Squadron Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Squadron Capital Management held 52 positions worth $273M, up 16% from $236M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Squadron Capital Management's Q1 2026 filing shows 19 new, 8 increased, 8 reduced and 15 closed positions. Its largest new stake was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M. The largest sale was Maze Therapeutics, an estimated $10.3M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Miscellaneous.
- Squadron Capital Management's largest Q1 2026 buy was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
- Squadron Capital Management added most to Relmada Therapeutics in Q1 2026, an estimated $8.4M increase.
- Squadron Capital Management's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $10.3M.
- Squadron Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $7.68M.
- Squadron Capital Management's ten largest holdings make up 67% of its $273M portfolio in Q1 2026.
- Squadron Capital Management opened 19 new positions and closed 15 in Q1 2026.
- Squadron Capital Management's portfolio value rose 16% quarter-over-quarter to $273M.
Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.